The Lancet Haematology
Fecha de publicación: 24 February 2020
DOI: https://doi.org/10.1016/S2352-3026(19)30283-2
Autores: Christopher P Fox, MD., Monica Civallero, PhD., Young-Hyeh Ko, MD., Martina Manni, PhD., Tetiana Skrypets, MD., Prof Stefano Pileri, MD
et al.
Background: Extranodal natural killer (NK) T-cell lymphoma (ENKTL) is a unique clinicopathological entity, typically associated with poor survival outcomes. Most published data have come from east Asian study groups, with little information available from international cohorts. The effects of treatment advances on routine clinical practice across continental territories has not been clear. We aimed to improve understanding of the clinical characteristics and outcomes of patients with ENKTL.
Leer más
Comentarios
Para dejar un comentario antes debes iniciar sesión:
¿No tienes una cuenta?
Regístrate a través de éste enlace.